ESSA Pharma Inc. recently announced early data from its Phase 1 clinical trial for EPI-506, an anti-tumor drug.
The drug was well-tolerated and showed an acceptable level of safety; no serious adverse events were reported in patients involved in the study.
Prostate cancer specialist, Dr. Kim Chi, of the BC Cancer Agency in Vancouver, presented the findings from the study at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago. The presentation was titled, “Efficacy, safety, tolerability and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor ("AR") N-terminal domain ("NTD") inhibitor, in men with metastatic castration-resistant prostate cancer ("mCRPC") progressing after enzalutamide and/or abiraterone.”
“To see some indication of PSA responses in such a heavily treated patient population is encouraging. Given the acceptable safety and tolerability seen to date, we look forward to additional data that will be forthcoming from patients receiving higher doses of EPI-506,” Chi said. “Prostate cancer is the second-most common cancer in men. Despite the therapeutic advances made in recent years, prostate cancer patients eventually progress on these treatments, so finding new options to complement or follow these therapies is absolutely essential.”